Celemics reports sharp revenue decline and large net loss in Q1 2026, secures liquidity through capital raising

Consolidated Q1 2026 revenue KRW 923M (down 46.4% YoY from KRW 1,723M), operating loss KRW 1,426M (vs loss of KRW 447M), net loss KRW 6,047M (vs loss of KRW 2,247M). Standalone revenue KRW 785M, operating loss KRW 1,389M, net loss KRW 6,007M.
Net loss widened mainly due to KRW 4,689M valuation loss on financial assets at FVTPL and increased operating loss from revenue decline.
In Feb 2026, issued KRW 4B face value 1st unregistered private convertible bonds (conversion price KRW 2,966, maturity 2029). KRW 3B allocated to major shareholder Park Jong-gap.
In Apr 2026 (post-report), issued KRW 14.7B 2nd CB (conversion price KRW 8,324) and KRW 4.293B third-party allotment equity offering (issue price KRW 2,629, 1,632,829 shares) for working capital.
Change in major shareholder: Kim Hyo-ki and another transferred 429,933 shares to Park Jong-gap, making Park the new major shareholder (5.97% stake). Kim holds 2.94%.
Consolidated total assets KRW 22.87B (year-end 2025: KRW 24.41B), total liabilities KRW 5.36B (year-end KRW 1.39B) increased due to CB issuance. Total equity KRW 17.50B (year-end KRW 23.02B).
Operating cash flow negative at KRW -1.21B (Q4 2025: KRW -1.47B).
Target Capture kit revenue (products) KRW 597M (vs KRW 1,253M), NGS service revenue KRW 327M (vs KRW 461M). Overseas revenue share 29.7%.
R&D expenses KRW 261M (28.3% of revenue), up from KRW 215M. Ongoing government R&D projects.
No contingent liabilities or pending lawsuits.

ADVERTISEMENT (250px+)